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Abstract
Background: Little is known about drug cost communications of Medicare Part D beneficiaries with chronic 
conditions such as diabetes. The purpose of this study is to assess Medicare Part D beneficiaries with diabetes' levels of 
communication with physicians regarding prescription drug costs; the perceived importance of these 
communications; levels of prescription drug switching due to cost; and self-reported cost-related medication non-
adherence.
Methods: Data were obtained from a cross-sectional survey (58% response rate) of 1,458 Medicare beneficiaries with 
diabetes who entered the coverage gap in 2006; adjusted percentages of patients with communication issues were 
obtained from multivariate regression analyses adjusting for patient demographics and clinical characteristics.
Results: Fewer than half of patients reported discussing the cost of medications with their physicians, while over 75% 
reported that such communications were important. Forty-eight percent reported their physician had switched to a 
less expensive medication due to costs. Minorities, females, and older adults had significantly lower levels of 
communication with their physicians regarding drug costs than white, male, and younger patients respectively. 
Patients with < $25 K annual household income were more likely than higher income patients to have talked about 
prescription drug costs with doctors, and to report cost-related non-adherence (27% vs. 17%, p < .001).
Conclusions: Medicare Part D beneficiaries with diabetes who entered the coverage gap have low levels of 
communication with physicians about drug costs, despite the high perceived importance of such communication. 
Understanding patient and plan-level characteristics differences in communication and use of cost-cutting strategies 
can inform interventions to help patients manage prescription drug costs.
Background
The Medicare Part D outpatient drug coverage benefit,
instituted in January 2006, was in many ways a response
to rising drug costs for seniors [1-3]. However, the stan-
dard Part D benefit contains a coverage "gap" in prescrip-
tion drug cost coverage. In 2006, a period of no coverage
for drug costs began when total drug costs reached
$2,250 (after an initial $250 deductible and 25% coinsur-
ance rate up to this point), and continued until patients
reach an out-of-pocket maximum of $3,600 [4].
Out-of-pocket expenses comprise up to 20% of health
care costs in the U.S. [5]. While physicians can play an
important role in reducing out-of-pocket drug cost bur-
den for their Medicare Part D patients [6-8], studies sug-
gest that patients and physicians communicate
infrequently about out-of-pocket costs [5,7,9,10] and that
this communication occurs less often than either of them
would like [5,7,8].
Patients with chronic illnesses such as diabetes may be
at particular risk for high drug costs, given their need for
multiple medications to treat their diabetes and accom-
panying comorbid conditions [11-13]; these factors may
also make them more liable to experience cost-related
medication non-adherence [14]. Despite this increased
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vulnerability, there is little information on how often Part
D beneficiaries with diabetes or other chronic illnesses
communicate about drug costs with physicians.
Previous studies suggest that patient characteristics
(e.g. race/ethnicity) are associated with how likely
patients are to communicate with their physicians about
drug costs, and with how much they would like to discuss
costs with their providers [5,7,9]. Communication may
also potentially vary by the wide variety of Part D plan
structures and benefits offered to patients [15], including
by whether beneficiaries enroll in Medicare Advantage
Prescription Drug Plans (MAPDs) that offer a wide range
of health care services along with drug coverage or Pre-
scription Drug Plans (PDPs) that offer drug coverage as a
stand-alone benefit. However, this relationship has not
been explored. The purpose of this report is to examine
drug cost communication levels, prescription drug
switching by physicians, and self-reported medication
non-adherence among Medicare Part D beneficiaries
with diabetes, and to assess how these vary across such
characteristics.
Methods
The Translating Research into Action for Diabetes
(TRIAD) study is a multi-center study of diabetes care in
managed care settings [16]. Within a subset of health
plans participating in TRIAD, a cross-sectional survey
was conducted from April-October 2007 to examine the
implementation of the Medicare Part D drug benefit
among beneficiaries with diabetes. Potential survey
respondents were enrolled in one of three types of health
insurance products in 2006: 1) for-profit Medicare
Advantage Prescription Drug (MAPD) plans within eight
states, 2) stand-alone, for-profit Medicare Prescription
Drug Plans (PDPs) in the same eight states, and 3) an
MAPD product offered by a large, integrated delivery sys-
tem model HMO in California (IDS MAPD). The multi-
state plan is a network-model system offering two differ-
ent Part D benefit designs. One design had a standard
coverage gap between $2,250 in total drug costs and
$3,600 in out-of-pocket drug costs, and the other pro-
vided generic-only medication coverage during this gap.
Beneficiaries could have either of the cost-sharing
designs through an MAPD plan or through a stand-alone
PDP plan. During the coverage gap, beneficiaries that
were enrolled in a plan with generic-only coverage con-
tinued to have an $8.50 generic copayment but no cover-
age for brand name drugs, while those with a complete
gap in coverage paid full cost for all drugs including
generics. Patients in the IDS-MAPD may have had sup-
plemental gap coverage.
To be eligible for the survey, patients were required to
have been continuously enrolled in one of the two MAPD
plans from 1/01/05 to 12/31/06, or newly enrolled in the
PDP plan between 11/15/05 and 3/01/06, and must have
hit the Part D coverage gap in expenditures (i.e. had total
2006 drug expenditures that reached $2,250) by October
1, 2006. Previous work suggests that more than 25% of
diabetes patients enter the coverage gap annually [17].
Among eligible patients who were beneficiaries in the
participating plans, the survey randomly sampled mem-
bers who were at least 65 years old, spoke English or
Spanish. Drug expenditures were obtained using claims
data. Patients who could not provide informed consent or
were too ill to participate were excluded. Beneficiaries
who were low-income subsidy (LICS) qualifiers were also
excluded because their Part D benefit does not include a
coverage gap. Potential participants were sent a $10 gift
card as an incentive, and offered the option of completing
a computer-assisted telephone interview or a written sur-
vey.
The survey response rate was 58%. Respondents were
not significantly different from non-respondents in terms
of gender, number of medications, or geocoded census-
track income, and differed less than one year in mean age
(data not shown); data are unweighted and did not adjust
for non-response.
Survey participants were asked if, during 2006, they 1)
thought the issue of prescription drug cost was important
enough to raise with their doctor; 2) wanted their doctor
to consider the cost to them when choosing medication;
and 3) talked with any doctor about the amount they had
to pay for prescription drugs. Responses to the first ques-
tion was given on a 4-point Likert scale, and dichoto-
mized for analysis into 'strongly agree/agree' vs. 'disagree/
strongly disagree/don't know,' while responses for the last
two questions were given as 'yes/no'. Patients were also
asked if their doctor switched any prescriptions to a less
expensive medication because of cost, or if they had used
any medication less often than the doctor prescribed due
to the amount they had to pay in 2006 (responses given as
'yes/no').
Multiple logistic regression models were used to create
adjusted percents of patients across demographic and
health plan characteristics responding 'strongly agree/
agree' or 'yes' to the above questions (dependent vari-
ables), adjusting for patient demographics, self-rated
health status, and a comorbidity score based on a simple
sum of 14 self-reported health conditions obtained
through the survey (independent variables). Adjusted
percents are calculated by setting all characteristics
except the variable of interest to the mean, using the coef-
ficients from the model as multipliers. Since the average
number of patients per prescribing physician was very
low (mean of 1.5 patients per prescribing physician),
models did not adjust for patient clustering within physi-
cian. Models also adjusted for month entering the gap,
number of unique medications taken during 2006, per-Schmittdiel et al. BMC Health Services Research 2010, 10:164
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centage of medications in the first quarter that were
generic, and difference between total and out-of-pocket
medication costs in the first quarter (obtained through
claims data). Analyses were performed using SAS v9.2.
This study was developed and approved by the Steering
Committee of the Translating Research in Action for Dia-
betes (TRIAD) Study and conducted by researchers in
two of TRIAD's Translational Research Centers, and
approved by the appropriate Institutional Review Boards.
Results
A total of 1,458 beneficiaries with diabetes entered the
coverage gap in 2006 and responded to the survey. Sev-
enty-four percent of patients were white, and 54% were
female. Forty-one percent of patients had an annual
household income of less than $25 K (Table 1).
Forty-four percent of patients reported discussing drug
costs with their physician in 2006, while 76% reported
wanting to have such discussions with physicians and
80% wanted their physician to consider costs when pre-
scribing medications (Table 2). Almost half reported that
a physician switched them to a less expensive version of
their medication due to cost.
After adjusting for other covariates, female patients
were more likely than male patients to report they wanted
doctors to consider costs when choosing medications
(84% vs. 78%, p < .05), and to report they used medica-
tions less often than prescribed due to cost (25% vs. 20%,
p < .05). Minority patients were less likely than whites to
report that they had discussed drug costs with MDs (37%
vs. 48%, p < .001). Patients age 65-74 were more likely to
discuss prescription drug costs with physicians than
those over 75 (50% vs. 41%, p < .001), and also were more
likely to report taking less medication due to cost (19% vs.
16%, p < .001). Patients with < $25 K annual household
income were more likely to think the issue of drug costs
were important enough to raise with their doctor (80%),
and also more likely to have talked about prescription
drug costs with doctors (51%) than patients with house-
hold incomes above $40 K annually. These patients also
reported more cost-related non-adherence (27% vs. 17%,
p < .01). There were no differences in patient-reported
communication, physician drug switching, or cost-related
non-adherence by level of patient education (data not
shown).
Patients in the IDS MAPD plan were less likely than
patients in the other two Part D plans to think the issue of
drug costs was important enough to raise with their doc-
tors (66% vs. 81% in for-profit MAPD and 79% in PDP, p <
.001), and were also less likely to actually have talked with
a doctor about prescription drug costs (36% vs. 50% in
for-profit MAPD and 51% in PDP, p < .01). IDS MAPD
patients reported slightly lower cost-related non-adher-
ence to medications than patients in the other two plans,
although this difference was not significant.
Table 1: Demographics of the Study Sample (n = 1458)
Mean (SD) or %
Age 75.0 (5.8)
65-69 years old (n = 293) 20%
70-74 years old (n = 443) 30%
75-79 years old (n = 415) 29%
80-84 years old (n = 218) 15%
85 plus (n = 89) 6%
Race/Ethnicity
White (n = 982) 74%
Latino (n = 212) 16%
Asian/Pacific Islander (n = 43) 3%
African American (n = 57) 4%
Other (n = 39) 3%
Female Gender (n = 793) 54%
Education
< High School (n = 269) 19%
High school graduate/some college 
(n = 822)
60%
4+ years college (n = 284) 21%
Annual Income
< $25 K (n = 491) 41%Schmittdiel et al. BMC Health Services Research 2010, 10:164
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Discussion
In this study, fewer than half of Medicare Part D benefi-
ciaries with diabetes who hit the coverage gap in 2006
had discussed out-of-pocket prescription drug costs with
any physician during that year. This is despite the fact
that all of the patients in the study had drug costs suffi-
cient to cause them to reach the prescription drug cost
coverage gap in 2006, and 22% reported using medica-
tions less often than prescribed due to cost. While fewer
than half of patients reported discussing drug costs with
physicians, more than three-quarters reported thinking
the issue of prescription drug costs was important
enough to raise with a doctor.
Forty-seven percent of patients reported that their phy-
sician had switched them to a less expensive medication
after considering patients' out of pocket costs. This find-
ing suggests that there was room for adjustment to lower
cost medications, and that many physicians are amenable
to considering medication costs in prescribing. The
recent health care reforms to Medicare Part D will con-
tinue to require significant medication cost-sharing for
patients as changes to the benefit are phased in during
the next 10 years, particularly for brand-name drugs [18].
Given that physicians do not always know the level of
patient out-of-pocket drug costs [19,20], and may have
difficulty identifying patients who have problems paying
for prescription drugs [7,21], health plans and medical
groups may want to consider organizational level inter-
ventions designed to facilitate these switches to lower
cost medications.
Patient characteristics such as gender, race/ethnicity,
income, and age were found to be related to patient-phy-
sician communication regarding prescription drug costs
and cost-related non-adherence. Minorities talked with
their physicians about drug costs less often than white
patients, while women, patients with < $40,000 annual
income, and younger beneficiaries were at higher risk for
cost-related medication non-adherence. This information
that gender, age, income, and race/ethnicity are related to
levels of drug cost communication and to self-reported
non-adherence could be of help to providers and health
plans in identifying patients who may need additional
help in initiating such conversations.
Significant differences were observed between patients
in MAPD plans offered through a not-for-profit inte-
grated delivery system (IDS-MAPD) and patients in for-
profit PDP or MAPD plans. Medicare beneficiaries in the
IDS-MAPD were much less likely to either think pre-
scription drug costs were important enough to raise with
their doctor or to actually discuss prescription drug costs
with their doctor than patients in the other two plans.
Despite this, IDS-MAPD patients had lower (although
not significantly) levels of cost-related medication non-
adherence among the plans. Both patients and providers
in the IDS-MAPD may perceive that much of what could
be done to reduce prescription costs had already
occurred within the current system. Patients and physi-
cians may feel that the managed care system stresses the
use of lower cost medications in its formulary and else-
where [22,23], and that patient out-of-pocket costs are
unlikely to be reduced through medication switching.
This study has a number of limitations that should be
noted. It is possible that Medicare Part D beneficiaries
with diabetes are communicating with other health care
providers such as diabetes educators and clinical pharma-
$25-40 K (n = 283) 24%
> $40 K (n = 418) 35%
Health Plan
Integrated Delivery System MAPD 
(n = 509)
35%
For-Profit MAPD (n = 772) 53%
For-Profit PDP (n = 177) 12%
Health Status
Excellent/Very Good (n = 188) 14%
Good (n = 454) 33%
Fair/Poor (n = 741) 53%
Comorbidity score (mean +/- SD) 
(range = 0-14)
4.9 (2.3)
Number of medications in 2006 14.4 (5.3)
Out-of-pocket med costs in Q1 2006 $359 (262)
Mean % of meds that are generic in Q1 
2006
66 (21)
Table 1: Demographics of the Study Sample (n = 1458)
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Table 2: Patient-Provider Communication Regarding Drug Costs
Patient/Plan 
Characteristics
Thought issue of 
drug costs important 
enough to raise with 
MD (% strongly 
agree/agree)
Wants MD to consider 
cost when choosing 
drugs (% yes)
Talked with MD 
about amount paid 
for drugs (% yes)
MD switched any 
drug to a less 
expensive version 
because of cost (% 
yes)
Used any drug less 
often than 
prescribed because 
of cost (% yes)
Overall Sample (n = 
1458)
76% 80% 44% 47% 22%
Adjusted Percents+
Female 78% 84%* 47% 51% 25%*
Male++ 74% 78% 43% 44% 20%
White++ 76% 81% 48% 49% 23%
Non-White 77% 80% 37%*** 43% 23%
Age 65-74 81%*** 83% 50%** 45% 29%***
Age 75++ 70% 79% 41% 51% 16%
Income < $25 K 80%* 82% 51%*** 47% 27%***
Income $25-40 K 78% 84% 49%*** 57%* 24%***
Income > $40 K++ 72% 78% 37% 41% 17%
Integrated Delivery 
System MAPD++
66% 77% 36% 33% 21%
For-Profit MAPD 81%*** 84%* 50%*** 53%*** 24%
For-Profit PDP 79%* 81% 51%** 57%** 26%
*p < .05, ** p < .01, *** p < .001
+ From models adjusted for age, gender, income, education, comorbidities, race/ethnicity, difference between total and OOP costs in first 
quarter (Q1) of 2006, % generic medications in Q1 of 2006, and month of gap entry.
++Referent Group.Schmittdiel et al. BMC Health Services Research 2010, 10:164
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cists about their prescription drug costs, and that these
findings under report overall communication. However,
the current survey also asked patients about communica-
tion with pharmacists regarding drug costs, and found
overall levels to be extremely low across plans. It is also
possible that geographic differences may underlie some
of the differences seen between the IDS-MAPD, for-
profit MAPD, and PDP plans. The IDS-MAPD plan was
only offered in California, which has a different health
care environment than that of other states [24]. The sur-
vey asks about experiences in 2006, but was not adminis-
tered until 2007; this delay may have biased responses to
reflect more recent experiences. Patients report that their
MD switched them to a less expensive drug due to cost
slightly more often than they report talking to their MD
about drug costs (47% vs. 44%); this may be due to factors
such as MDs acting without consulting patients, switches
initiated by pharmacists, or formulary switches when
new generics entered the market that cannot be mea-
sured in this study context. The survey sample is com-
prised mainly of patients in MAPD plans; since the
m a j o r i t y  o f  P a r t  D  b e n e f i c i a r i e s  n a t i o n a l l y  a r e  i n  P D P
plans [25], this may make our findings somewhat less
generalizable. Finally, this survey only sampled patients
who actually entered the Part D coverage gap; patients
who did not enter the gap may have different patterns of
provider communication than those in this analysis.
Conclusions
Medicare Part D beneficiaries with diabetes who hit the
coverage gap have relatively low levels of communication
with physicians about drug costs, despite the high level of
perceived importance of such communication. Under-
standing patient and plan-level differences in communi-
cation can help diabetes educators, physicians, and health
plans design and implement strategies to help patients at
risk for cost-related non-adherence manage their pre-
scription drug costs.
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